Literature DB >> 1922596

Continuous ambulatory peritoneal dialysis (CAPD) in patients with diabetic nephropathy.

F A Kemperman1, R van Leusen, F J van Liebergen, J Oosting, E W Boeschoten, D G Struijk, R T Krediet, L Arisz.   

Abstract

A 3-centre study was done to analyse the results of 70 patients with end-stage renal disease caused by diabetic nephropathy and treated with CAPD. Fifty patients had insulin-dependent diabetes (mean age 42, mean duration of diabetes 24 yr); 20 had non-insulin-dependent diabetes (mean age 61, mean duration 15 yr). Total treatment time was 1563 months and ranged from one to 83 months (median 18). Patient survival was 86% at 1 yr and 33% at 4 yr. Technique survival was 87% and 63%. Cox's multiple hazard regression analysis showed that age above 45 yr (relative risk 2.2), systolic hypertension (2.6) and cardiac disease (2.2) at the start of CAPD were associated with shorter patient survival. Metabolic control was good. Haemoglobin rose during the first 3 months. Plasma creatinine concentration increased with time, probably due to the loss of residual renal function. HbA1c levels were in the normal range for 60% of the patients. Mean hospital stay was 42 days per year, 26 as a consequence of vascular complications and 16 due to peritonitis and catheter-related problems. We conclude that CAPD is a good renal replacement modality for patients with diabetic renal failure. The patient survival is dependent on age, systolic hypertension and cardiac disease at the start of CAPD.

Entities:  

Mesh:

Year:  1991        PMID: 1922596

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  2 in total

Review 1.  Cardiovascular risk in the peritoneal dialysis patient.

Authors:  Raymond T Krediet; Olga Balafa
Journal:  Nat Rev Nephrol       Date:  2010-06-22       Impact factor: 28.314

2.  Efficacy of dialysis for the treatment of patients with diabetic nephropathy: Study protocol.

Authors:  De-Rong Shao; Yue Zhou
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.